Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.290
-0.040 (-3.01%)
At close: Mar 28, 2025, 4:00 PM
1.298
+0.008 (0.59%)
After-hours: Mar 28, 2025, 7:01 PM EDT
Alector Revenue
In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth. Alector had revenue of $54.24M in the quarter ending December 31, 2024, with 257.08% growth.
Revenue (ttm)
$100.56M
Revenue Growth
+3.60%
P/S Ratio
1.24
Revenue / Employee
$422,513
Employees
238
Market Cap
127.82M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALEC News
- 4 weeks ago - Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Alector to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call - GlobeNewsWire
- 2 months ago - Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 - GlobeNewsWire
- 4 months ago - Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Benzinga
- 4 months ago - Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce - Benzinga
- 4 months ago - Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update - GlobeNewsWire